Streptomycin

Streptomycin holds the distinction of being the first aminoglycoside antibiotic discovered, isolated from Streptomyces griseus by Selman Waksman and colleagues in 1943, and it fundamentally transformed the treatment of bacterial infections in both human and veterinary medicine. This historically significant antibiotic demonstrates bactericidal activity against a range of gram-negative bacteria and was the first effective treatment for tuberculosis, revolutionizing infectious disease management in the mid-twentieth century. In veterinary medicine, streptomycin has served as a valuable tool for treating bacterial infections in food-producing animals, though its role has evolved as newer antibiotics have become available and bacterial resistance patterns have changed over the decades of its use.

The mechanism of action of streptomycin involves irreversible binding to the 30S ribosomal subunit of susceptible bacteria, specifically to the 16S ribosomal RNA component, which causes misreading of the genetic code and inhibition of protein synthesis. This interaction produces aberrant proteins that damage bacterial cell membranes and ultimately lead to cell death, providing the bactericidal activity that characterizes aminoglycoside antibiotics. Like other aminoglycosides, streptomycin demonstrates concentration-dependent killing, meaning that higher peak concentrations relative to the minimum inhibitory concentration result in more effective and rapid bacterial elimination. The drug also exhibits a post-antibiotic effect where bacterial suppression continues for a period after drug concentrations fall below inhibitory levels.

Streptomycin is available primarily as an injectable formulation for intramuscular or subcutaneous administration in food animals. Historically, combination products pairing streptomycin with penicillin were widely used to provide broad-spectrum coverage against both gram-positive and gram-negative bacteria, and some such combination products remain available for veterinary use. The streptomycin-penicillin combination exemplifies synergistic antibiotic therapy, with penicillin disrupting bacterial cell wall synthesis to enhance aminoglycoside entry into bacterial cells, improving efficacy against certain pathogens. Pure streptomycin products may be less commonly available in current veterinary supply chains compared to its historical prominence.

The regulatory status of streptomycin in food-producing animals reflects both its long history of use and evolving concerns about antimicrobial resistance and food safety. Approved uses in cattle and swine exist for specific indications, with established withdrawal times designed to ensure that drug residues do not enter the food supply at violative levels. The emergence of widespread streptomycin resistance among many bacterial pathogens has reduced the drug's clinical utility compared to earlier decades, though it retains value for specific indications where susceptible organisms are documented. Veterinary oversight ensures appropriate use according to current therapeutic principles and regulatory requirements.

Streptomycin is indicated for the treatment of bacterial infections caused by susceptible gram-negative organisms in cattle and swine, with particular historical importance in treating leptospirosis, a zoonotic disease caused by spirochete bacteria of the genus Leptospira. Leptospirosis in cattle causes significant reproductive losses including abortion, stillbirth, and infertility, while also posing public health risks through contamination of water and soil with infected urine. Streptomycin's activity against leptospiral organisms made it a mainstay of leptospirosis treatment for decades, and it remains useful for eliminating the renal carrier state in infected animals that otherwise shed organisms into the environment.

Bacterial enteritis caused by Escherichia coli and other susceptible gram-negative enteric pathogens represents another traditional indication for streptomycin in food animals. In young calves and piglets, acute bacterial enteritis can rapidly progress to life-threatening dehydration and septicemia without effective antimicrobial intervention. Streptomycin's bactericidal activity provides rapid reduction in bacterial load when administered parenterally, though oral absorption is negligible and systemic administration is required for therapeutic effect. The drug has been used both as monotherapy and in combination with penicillin for treating mixed gram-positive and gram-negative infections.

Respiratory infections caused by susceptible gram-negative bacteria have historically been treated with streptomycin, though changing resistance patterns have reduced its utility for this indication. Pasteurella and other respiratory pathogens that were once reliably susceptible to streptomycin now frequently demonstrate resistance, necessitating culture and sensitivity testing to guide antibiotic selection. When susceptibility is confirmed, streptomycin may still provide effective therapy for bacterial pneumonia and other respiratory tract infections. The streptomycin-penicillin combination extends coverage to include gram-positive respiratory pathogens like streptococci.

Combination therapy with penicillin expands streptomycin's therapeutic applications by providing synergistic activity against certain pathogens and broad-spectrum coverage when the specific causative organism is unknown. The combination is particularly valuable in mixed infections involving both gram-positive and gram-negative bacteria, as commonly occurs in wound infections, peritonitis, and complicated soft tissue infections. Synergistic bactericidal activity against enterococci and certain other organisms provides enhanced efficacy compared to either agent alone for specific pathogens where synergy is documented.

Extra-label uses of streptomycin may extend to treatment of various bacterial infections when culture and sensitivity testing indicates susceptibility and no approved alternative exists for the specific indication. Such uses require a valid veterinarian-client-patient relationship and appropriate documentation, with extended withdrawal times determined through FARAD consultation to ensure food safety. The historical breadth of streptomycin experience provides some guidance for extra-label applications, though the increasing prevalence of resistant organisms limits the situations where streptomycin represents an optimal therapeutic choice.

Injectable streptomycin for cattle is typically administered at doses ranging from 10 to 25 milligrams per kilogram of body weight daily, with specific dosing depending on the indication, severity of infection, and product formulation. For treatment of leptospirosis and elimination of the carrier state, higher doses within this range administered for three to five consecutive days have traditionally been recommended to achieve adequate drug concentrations in renal tissue where Leptospira organisms persist. The intramuscular route provides reliable absorption and predictable blood levels, while subcutaneous administration offers an alternative with similar pharmacokinetic characteristics. Injection in the neck muscles is preferred for cattle destined for slaughter to minimize potential carcass defects.

Swine dosing protocols generally recommend streptomycin at 10 to 20 milligrams per kilogram body weight administered intramuscularly once or twice daily depending on the specific product and indication. For bacterial enteritis in young pigs, early intervention at the first signs of illness optimizes therapeutic outcomes, as delays allow bacterial proliferation and tissue damage that respond poorly to antimicrobial therapy alone. Injection sites should be selected to avoid prime cuts, with the neck muscles behind the ear representing appropriate locations that minimize economic impact from any injection site lesions. Treatment typically continues for three to five days or until clinical resolution.

Combination streptomycin-penicillin products are administered according to the specific product labeling, with doses calculated to deliver therapeutic amounts of both active ingredients simultaneously. These fixed-ratio combinations provide convenience for treating mixed infections but require attention to ensure that adequate doses of each component are delivered for the target pathogens. The volume of injection should be divided among multiple sites if the total exceeds appropriate limits for single-site administration to minimize tissue damage. Some combination products are formulated for once-daily administration, while others may require twice-daily dosing.

Administration technique significantly impacts both therapeutic efficacy and food safety outcomes with injectable streptomycin. Proper intramuscular injection requires selection of appropriate needle gauge and length based on animal size, ensuring that the drug is deposited in muscle tissue rather than subcutaneous fat or inadvertently into blood vessels. Aspiration before injection confirms that the needle has not entered a blood vessel. The injection site should be clean and dry, and the rubber stopper of multi-dose vials should be disinfected before each needle entry. Rotation of injection sites prevents repeated trauma to the same tissue.

Route of administration affects streptomycin pharmacokinetics and therapeutic applications. Oral administration is not effective for systemic infections because streptomycin is poorly absorbed from the gastrointestinal tract, though this property has been exploited for local intestinal effects in some applications. Intramuscular administration provides reliable systemic absorption with peak concentrations achieved within one to two hours. Subcutaneous injection results in somewhat delayed absorption compared to intramuscular administration but may produce less tissue reaction. Intravenous administration achieves immediate peak levels but is not routinely used and may be associated with increased adverse effects.

Withdrawal times for streptomycin products must be strictly observed to ensure that drug residues do not enter the food supply at violative levels. Labeled withdrawal times vary by product but typically range from approximately 30 days for meat. Milk from treated dairy animals must be discarded for extended periods, with specific durations depending on product labeling. For extra-label uses, FARAD should be consulted for appropriate extended withdrawal recommendations that may substantially exceed labeled periods. Proper record-keeping of all streptomycin treatments is essential for compliance with food safety regulations and residue avoidance programs.

Streptomycin shares the nephrotoxicity and ototoxicity concerns characteristic of aminoglycoside antibiotics, representing the most serious potential adverse effects associated with its use in food-producing animals. Nephrotoxicity results from drug accumulation in renal tubular epithelial cells, causing acute tubular necrosis that manifests as decreased urine output, increased blood urea nitrogen and creatinine concentrations, and electrolyte disturbances. Risk factors for nephrotoxic effects include pre-existing renal disease, dehydration, concurrent administration of other nephrotoxic agents, and prolonged treatment duration. The nephrotoxic potential necessitates attention to patient hydration status and limitation of treatment duration to minimize cumulative drug exposure.

Ototoxicity affects both vestibular and auditory function, resulting from streptomycin accumulation in inner ear fluids and destruction of sensory hair cells in the vestibular apparatus and cochlea. Vestibular toxicity manifests as head tilt, ataxia, circling, nystagmus, and difficulty maintaining balance, while cochlear toxicity produces hearing loss that may not be readily apparent in livestock but can be profound and permanent. The ototoxic effects of streptomycin are typically irreversible because damaged hair cells do not regenerate, making prevention through appropriate dosing and duration paramount. Animals showing signs of vestibular disturbance during treatment should have streptomycin discontinued immediately.

Injection site reactions occur with variable frequency following intramuscular streptomycin administration, ranging from mild, transient swelling to significant tissue inflammation and persistent lesions. Local irritation at injection sites may cause discomfort and behavioral changes in treated animals, while more severe reactions can result in abscess formation or tissue necrosis requiring intervention. In animals destined for slaughter, injection site lesions may persist to processing, resulting in carcass trim and economic loss. Proper injection technique, appropriate injection volumes per site, and rotation of injection locations help minimize injection site complications.

Neuromuscular blockade represents a potential serious adverse effect of streptomycin, particularly when combined with anesthetic agents or neuromuscular blocking drugs during surgical procedures. Aminoglycosides inhibit neuromuscular transmission through both presynaptic and postsynaptic mechanisms, causing muscle weakness and potentially respiratory paralysis. This effect is dose-dependent and more likely with rapid intravenous administration, elevated serum concentrations, or in animals with underlying neuromuscular conditions. Calcium gluconate can help reverse aminoglycoside-induced neuromuscular blockade, and affected animals may require ventilatory support until drug levels decline.

Hypersensitivity reactions to streptomycin occur occasionally, manifesting as urticaria, angioedema, or potentially severe anaphylactic reactions in sensitized animals. Animals with documented previous allergic reactions to streptomycin or other aminoglycoside antibiotics should not receive the drug again, as subsequent exposures may trigger progressively more severe responses. Cross-reactivity among different aminoglycoside antibiotics is possible, warranting caution in animals with any aminoglycoside hypersensitivity history. Emergency treatment supplies including epinephrine should be available when administering streptomycin, particularly when treating animals with unknown medication histories.

Streptomycin is contraindicated in animals with known hypersensitivity to aminoglycoside antibiotics, including streptomycin, gentamicin, neomycin, amikacin, and related compounds. Previous allergic reactions manifesting as skin reactions, respiratory distress, or anaphylaxis indicate that the drug should not be administered again. Cross-reactivity among different aminoglycosides means that animals hypersensitive to any drug in this class may react adversely to streptomycin, necessitating selection of antibiotics from alternative chemical families. Documentation of adverse reactions in medical records helps prevent inadvertent re-exposure in animals with aminoglycoside hypersensitivity.

Pre-existing renal impairment represents a significant contraindication for streptomycin use due to the drug's inherent nephrotoxic potential and dependence on renal elimination. Animals with acute kidney injury, chronic renal disease, or laboratory evidence of compromised renal function face substantially increased risk of developing severe or fatal nephrotoxicity if given streptomycin. Drug accumulation occurs when renal clearance is reduced, leading to higher tissue concentrations and greater toxicity. Dehydration, which is common in animals with infectious diseases, should be corrected before initiating aminoglycoside therapy to optimize renal perfusion and drug clearance.

Concurrent use of streptomycin with other ototoxic or nephrotoxic medications is contraindicated due to additive or synergistic toxicity risks. Loop diuretics such as furosemide potentiate both nephrotoxic and ototoxic effects of aminoglycosides and should not be used concurrently unless absolutely necessary with careful monitoring. Other aminoglycoside antibiotics, certain cephalosporins, amphotericin B, and cisplatin are among the drugs with known nephrotoxic potential that should be avoided during streptomycin therapy. When combination therapy is unavoidable, enhanced monitoring for toxicity signs is essential.

Pregnancy presents relative contraindications for streptomycin use due to potential fetal effects, particularly ototoxicity resulting from aminoglycoside accumulation in fetal inner ear structures. While streptomycin has been used to treat leptospirosis in pregnant cattle to prevent abortion, the risk-benefit analysis must consider potential fetal harm alongside the consequences of untreated infection. When treatment during pregnancy is necessary, the shortest effective course at the lowest effective dose should be employed. Alternative antibiotics with better established fetal safety profiles should be considered when effective options exist.

Concurrent administration of streptomycin with other aminoglycoside antibiotics is strongly contraindicated due to additive nephrotoxicity and ototoxicity that substantially increases the risk of serious adverse effects. Combining streptomycin with gentamicin, neomycin, or amikacin offers no therapeutic advantage over single-agent therapy while dramatically elevating toxicity risk. Sequential therapy with different aminoglycosides should also be avoided, with adequate washout periods between agents if such treatment becomes necessary. Selection of antibiotics from different classes provides safer options when combination or sequential therapy is indicated.

Penicillin antibiotics are intentionally combined with streptomycin in commercial veterinary products to exploit synergistic antibacterial activity, representing a beneficial drug interaction that extends antimicrobial coverage. The combination demonstrates enhanced bactericidal activity against enterococci and certain other organisms through complementary mechanisms where penicillin-induced cell wall damage enhances streptomycin uptake into bacterial cells. These combination products are specifically formulated to provide optimal ratios of active ingredients. However, physical incompatibility can occur when these drugs are mixed in the same syringe, necessitating use of pre-formulated combination products or separate administration.

Loop diuretics, particularly furosemide, interact with streptomycin to potentiate both nephrotoxic and ototoxic effects through multiple mechanisms. The diuretic-induced alterations in inner ear fluid dynamics and effects on renal tubular function enhance aminoglycoside toxicity to these organs. When diuretic therapy is essential in animals receiving streptomycin, thiazide diuretics may present less interaction risk than loop diuretics, though monitoring remains important. If loop diuretic use is unavoidable, extended intervals between administrations of the two drugs may partially mitigate the interaction.

Neuromuscular blocking agents and anesthetic drugs interact with streptomycin to produce enhanced or prolonged muscle paralysis and respiratory depression. The aminoglycoside contributes to neuromuscular blockade through mechanisms independent of the blocking agents themselves, potentially causing dangerous cumulative effects during surgical procedures. Anesthesiologists should be informed of recent streptomycin administration when planning procedures involving neuromuscular blockade. Reduced doses of blocking agents and extended monitoring during recovery may be necessary in streptomycin-treated animals.

Human safety precautions are essential when handling streptomycin products due to the potential for allergic sensitization through occupational exposure. Repeated skin contact with aminoglycoside antibiotics can cause contact dermatitis in sensitized individuals, and more serious hypersensitivity reactions may occur with subsequent exposures. Handlers should wear protective gloves when preparing and administering streptomycin injections to minimize skin contact. Accidental self-injection requires immediate medical attention due to risks of local tissue reaction and systemic aminoglycoside exposure. Pregnant women should avoid handling aminoglycoside antibiotics due to potential fetal ototoxicity.

Food safety considerations mandate strict adherence to withdrawal time requirements to prevent violative drug residues in meat and milk entering the human food supply. Streptomycin residues can contribute to antimicrobial resistance development and may cause adverse effects in individuals with aminoglycoside hypersensitivity. Record-keeping requirements include documentation of all treatments with drug identification, dose, route, dates, animal identification, and calculated withdrawal dates. Animals must not be sold for slaughter and milk must not be sold for human consumption until appropriate withdrawal periods have elapsed.

Antimicrobial resistance stewardship is particularly important for streptomycin given the widespread resistance that has developed among many bacterial pathogens over decades of use. Streptomycin should be reserved for infections confirmed or strongly suspected to be caused by susceptible organisms, with culture and sensitivity testing guiding treatment decisions when feasible. The historical pattern of rapidly emerging streptomycin resistance during treatment courses highlights the importance of adequate dosing and appropriate treatment duration. Using streptomycin for infections caused by resistant organisms contributes to resistance spread without providing therapeutic benefit.

Environmental protection requires proper disposal of unused medication, containers, and administration materials to prevent environmental antibiotic contamination. Streptomycin should not be disposed of through drains or into water sources where it can affect environmental bacteria and contribute to resistance selection. Empty containers should be properly managed according to local pharmaceutical waste regulations. Used syringes and needles must be disposed of in appropriate sharps containers to prevent human injury and environmental contamination.

Monitoring during streptomycin therapy should include observation for clinical response to treatment and signs of potential nephrotoxicity or ototoxicity. Animals should demonstrate improvement in clinical signs within 24 to 72 hours of initiating effective therapy for susceptible infections. Development of head tilt, ataxia, or balance disturbances suggests vestibular toxicity requiring immediate treatment discontinuation. Changes in urination patterns or signs of fluid imbalance may indicate nephrotoxic effects. In valuable animals, periodic assessment of renal function markers may provide early detection of nephrotoxicity.

Streptomycin products should be stored at controlled room temperature between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), protected from light that can degrade the active ingredient. Injectable solutions should remain in original vials with stoppers intact until use, stored in secure locations inaccessible to unauthorized persons and animals. Freezing should be avoided as it may affect drug stability and formulation integrity. Expiration dates should be checked before each use, and products showing discoloration, precipitates, or other evidence of degradation should not be used and should be properly disposed.

Multi-dose vials require proper handling techniques to maintain sterility throughout the use period. The rubber stopper should be cleaned with alcohol before each needle penetration, and a new, sterile needle should be used for each entry to prevent contamination and stopper coring. Once opened, multi-dose vials have limited beyond-use dating, typically 28 days unless otherwise specified by the manufacturer, and the date of first penetration should be recorded on the vial. Visual inspection before each use should confirm that the solution remains clear and free of particulates indicating contamination or degradation.

Disposal of streptomycin products and associated materials must follow proper pharmaceutical waste protocols to protect human health and the environment. Unused or expired medication should not be disposed of through household waste or drains where it can contaminate water systems. Pharmaceutical take-back programs or hazardous waste collection services provide appropriate disposal options. Empty containers may require triple-rinsing before disposal as regular waste in some jurisdictions, and used syringes and needles must be placed in puncture-resistant sharps containers for disposal as biohazardous waste according to local regulations.

Species-specific pharmacokinetic differences influence streptomycin dosing and therapeutic applications across livestock species, with cattle and swine demonstrating variations in drug distribution, metabolism, and elimination that affect both efficacy and safety. Cattle generally require doses in the higher range to achieve therapeutic concentrations in target tissues, particularly for leptospirosis treatment where renal tissue levels are important for eliminating the carrier state. Breed differences in body composition may affect drug distribution, with leaner cattle potentially demonstrating different pharmacokinetics than breeds with higher body fat content. Young calves may require dose adjustment based on their reduced renal function compared to adult animals.

Swine pharmacokinetics for streptomycin generally support dosing within established ranges across breeds, though individual variation in body composition may influence drug distribution. Modern lean genetic lines differ substantially in body composition from heritage breeds, potentially affecting volumes of distribution and drug concentrations achieved at given doses. Neonatal piglets have reduced capacity for drug elimination compared to growing pigs, warranting attention to dosing and treatment duration in very young animals. The relatively limited current use of streptomycin in swine compared to historical applications means that contemporary breed-specific data may be limited.

Small ruminants including sheep and goats may be treated with streptomycin under extra-label protocols when appropriate, with attention to species-specific considerations. Like cattle, sheep and goats are ruminants with complex forestomach systems, though their smaller body size may result in different pharmacokinetic profiles. Withdrawal time recommendations for small ruminants may differ from cattle, and FARAD guidance should be consulted for extra-label applications. The susceptibility of sheep to certain medications that are well-tolerated by other ruminants warrants caution when extrapolating dosing from cattle.

Production type influences streptomycin use decisions, particularly in dairy cattle where milk withdrawal requirements have significant economic implications. Beef cattle face prolonged meat withdrawal times that may affect marketing decisions, particularly if treatment occurs close to anticipated sale dates. The extended withdrawal periods associated with streptomycin compared to some alternative antibiotics may make it less attractive for animals with near-term marketing plans. These economic considerations should be discussed with producers when making treatment decisions.

Other aminoglycoside antibiotics represent the closest therapeutic alternatives to streptomycin, sharing mechanisms of action and antimicrobial activity patterns while differing in specific characteristics and clinical applications. Gentamicin offers broader gram-negative coverage including activity against Pseudomonas aeruginosa and demonstrates greater potency against many contemporary bacterial isolates due to less widespread resistance. Neomycin is primarily used for enteric infections via oral administration, exploiting its poor systemic absorption to achieve local intestinal effects. Amikacin demonstrates the broadest spectrum among aminoglycosides and retains activity against many streptomycin-resistant organisms but is considerably more expensive and less commonly available for food animal use.

Fluoroquinolone antibiotics such as enrofloxacin and danofloxacin offer alternative approaches to treating gram-negative infections in food animals with different mechanisms of action and resistance patterns. These concentration-dependent bactericidal agents achieve excellent tissue penetration and demonstrate activity against many pathogens targeted by streptomycin. However, regulatory restrictions on fluoroquinolone use in food animals due to resistance concerns have limited their availability and appropriate indications. When fluoroquinolones are selected, careful adherence to approved uses and withdrawal requirements is essential.

Tetracycline antibiotics including oxytetracycline provide broad-spectrum coverage against many bacterial pathogens with long histories of use in food animal production and established safety profiles. While bacterial resistance to tetracyclines is common among many organisms, susceptible isolates respond well to these cost-effective antibiotics. Tetracyclines also demonstrate activity against certain organisms outside the aminoglycoside spectrum, including some rickettsial and chlamydial pathogens. The different toxicity profile of tetracyclines compared to aminoglycosides may make them preferable in animals with renal concerns.